Scientific and Medical Equipment House

Scientific and Medical Equipment House

TTADAWUL:4014
26.00
SAR
-0.68
(-2.55%)
0.85EPS
32.00P/E
881.40MMarket Cap
Nov 05Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
18.53
19.46
19.9
21.75
23.32
23.79
25.89
29.24
29.22
26.22
Basic EPS, GAAP
1.65
2.27
2.36
2.49
2.58
0.59
1.34
0.87
0.95
0.92
Free Cash Flow per Basic Share
2.6
-3.11
5.43
3.91
-2.82
4.3
-5.18
9.38
0.04
2.52
Dividend per Share
- -
- -
- -
- -
- -
0.67
- -
1
1
- -
Book Value per Share
- -
10.02
11.86
14.27
15.78
15.68
17.03
17.02
16.96
16.62
Tangible Book Value per Share
- -
10.02
11.86
14.27
15.78
15.56
16.94
16.99
16.91
16.59
Basic Weighted Avg Shares
30
30
30
30
30
30
30
30
30
30
Sales/Revenue/Turnover
556
584
597
652
699
714
777
877
877
786
Operating Margin (%)
9.84
13.76
11.4
13.5
11.93
5.27
9.94
6.56
4.55
4.44
Depreciation Expense
- -
- -
- -
- -
- -
18
23
20
18
16
Net Income, GAAP
49
68
71
75
78
18
40
26
28
28
Effective Tax Rate (%)
13.53
13.55
0.46
9.07
9.53
43.7
24.35
31.93
34.74
30.24
Profit Margin (%)
8.89
11.66
11.84
11.46
11.08
2.46
5.16
2.98
3.24
3.5
Working Capital
279
344
356
401
467
456
493
509
505
493
LT Debt
- -
- -
4
6
13
20
20
16
13
17
Total Equity
- -
302
358
430
474
469
507
505
501
490
Return on Invested Capital (%)
- -
- -
11.5
13.29
11.04
3
7.72
5.01
3.74
3.35
Return on Capital (%)
- -
- -
15.62
14.74
13.43
4.43
8.16
5.92
6.09
5.92
Return on Common Equity (%)
- -
- -
21.53
19.07
17.2
3.72
8.17
5.12
5.58
5.35

Capital Structure

SAR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
179
167
216
LT Borrowings
5
4
11
LT Finance Leases
8
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
952
942
881

Working Capital

SAR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
855
851
921
Cash, Cash Equivalents & STI
20
40
80
Accounts Receivable, Net
525
478
528
Inventories
66
61
56
Total Current Liabilities
350
348
428
Payables & Accruals
- -
- -
- -
ST Debt
179
167
216
Deferred Revenue
- -
- -
- -

Growth Rates

SAR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.21%
-0.82%
Free Cash Flow
- -
-205.1%
-99.57%
Net Income, GAAP
- -
5.68%
8.68%
Sales/Revenue/Turnover
- -
6.19%
-0.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
216
215
218
227
877
2025
222
272
201
182
877
2026
192
212
- -
- -
- -

Quarterly Earnings Per Share

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.29
0.26
0.36
-0.04
0.87
2025
0.26
0.41
0.26
0.02
0.95
2026
0.28
0.36
- -
- -
- -

Quarterly Dividends Per Share

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Company Description

CEO
Faisal bin Hawas bin Farhan Al-Atawi
Full Time Employees
3,747
Sector
Consumer services
Industry
Other consumer services
Address
King Fahad Service Road Riyadh Riyadh Province Saudi Arabia 11441
IPO Date
Feb 28, 2022
Business
Scientific and Medical Equipment House Company (SMEH) (Ticker: 4014.SR) operates as a leading distributor of scientific, medical, and laboratory equipment in the Kingdom of Saudi Arabia. The company offers a comprehensive range of products and services, including laboratory instruments and consumables such as centrifuges, microscopes, and pipettes; medical diagnostic equipment like analyzers and imaging systems; scientific research tools encompassing spectrophotometers, incubators, and chromatography systems; as well as maintenance, calibration, and technical support services for healthcare and research institutions. Founded in 1977 and headquartered in Riyadh, Saudi Arabia, SMEH serves hospitals, universities, research centers, and industrial clients primarily within the Middle East region, with a focus on the Saudi public and private sectors. In recent developments, the company has expanded its operations through strategic partnerships with global manufacturers to enhance supply chain resilience amid regional healthcare growth, while maintaining steady performance without major acquisitions or funding rounds reported in the last two years.